预约演示
更新于：2025-05-16
Benidipine Hydrochloride
盐酸贝尼地平
更新于：2025-05-16
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H32ClN3O6 |
InChIKeyKILKDKRQBYMKQX-QABSGUMLSA-N |
CAS号91599-74-5 |
关联
54
项与 盐酸贝尼地平 相关的临床试验NCT06808321
Evaluation of Clinical Outcomes of Benidipine in Hypertensive And/or Chronic Coronary Syndrome Patients in the Turkish Population
CTR20244546
盐酸贝尼地平片（4mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
CTR20244393
盐酸贝尼地平片在中国健康受试者中单中心、开放、随机、单剂量、两制剂、两序列、四周期、完全重复交叉空腹及餐后状态下的生物等效性试验
100 项与 盐酸贝尼地平 相关的临床结果
登录后查看更多信息
100 项与 盐酸贝尼地平 相关的转化医学
登录后查看更多信息
100 项与 盐酸贝尼地平 相关的专利（医药）
登录后查看更多信息
631
项与 盐酸贝尼地平 相关的文献（医药）2025-04-29ACS Omega
Design, Characterization, and Evaluation of Solid-Self-Nano-Emulsifying Drug Delivery of Benidipine with Telmisartan: Quality by Design Approach
Article
作者: Pasha, Ismail ; Buddhadev, Sheetal S. ; Begum, M. Yasmin ; Garala, Kevinkumar C. ; Hani, Umme ; Baghel, Saurabh Singh ; Ahmed, Mohammed Muqtader ; Rahamathulla, Mohamed ; Alamri, Ali H.
The main purpose of this study was to design and develop a solid self-nanoemulsifying drug delivery system (S-SNEDDS) for the oral administration of benidipine (BD) and telmisartan (TEL) using the adsorption method with eucalyptus oil, Transcutol P, and Kolliphor EL via the Box-Behnken design approach. The prepared SNEDDS formulations were characterized using FTIR, DSC, SEM, and PXRD techniques and evaluated for zeta potential, refractive index, drug concentration, resistance to dilution, viscosity, and thermodynamic stability. Additionally, in vitro and stability studies were conducted. The results revealed that all prepared formulations (BT1-BT15) exhibited favorable zeta potential (17.2-28.39 mV) and polydispersity index (PDI) values (0.226-0.354). Among them, formulation BT11 demonstrated a desirable droplet size of 175.12 ± 2.70 nm, a PDI of 0.226, a zeta potential of -24.98 ± 0.18 mV, a self-emulsification time of 53.00 ± 2.10 s, a transmittance percentage of 99.6 ± 0.3%, and a drug release of 92.65 ± 1.70% within 15 min. BT11 exhibited significantly faster drug release compared to the commercially available product benidipine T (4 mg/40 mg) and the pure drugs BD and TEL, releasing more than 96% of both drugs in 0.1 N HCl within 60 min. Furthermore, BT11 demonstrated stability throughout the product's stability testing. These findings suggest that the oral S-SNEDDS formulation of BD and TEL can enhance the drugs' water solubility, potentially improving therapeutic outcomes and increasing patient compliance.
2025-03-24JACS Au
Synthetic Cation Transporters Eradicate Drug-Resistant Staphylococcus aureus, Persisters, and Biofilms
Article
作者: Feng, Yuhui ; Fong, Pak-Ming ; Pradeep, Halebeedu Prakash ; Tang, Victor Yat-Man ; Tao, Liang ; Yam, Bill Hin-Cheung ; Kao, Richard Yi-Tsun ; Xu, Lu ; Yang, Dan
New drugs are urgently required to address the ongoing health crisis caused by methicillin-resistant Staphylococcus aureus (MRSA) infections. Added to the challenge is the difficult-to-treat persister cells and biofilm which are tolerant to the antibiotics. Here we report a new approach to these problems, describing the design and synthesis of aminoxy-acid-based dipeptides that facilitate cation transport across cell membranes to disrupt bacterial ion homeostasis. Remarkably, these synthetic cation transporters display significant antibacterial activity against MRSA, while maintaining high selectivity over mammalian cells. They also effectively eliminate bacterial persisters and reduce established biofilms. Additionally, they inhibit biofilm formation and suppress bacterial virulent protein secretion, even at subinhibitory concentrations. Their associated antibiotic effects support their in vivo efficacy in murine skin and bloodstream MRSA infection models with no observable toxicity to the host. Mode-of-action analysis indicates that these cation transporters induce cytoplasmic acidification, hyperpolarization, and calcium influx, accelerating autolysis. Given their potent activity against bacterial persisters and biofilms, synthetic cation transporters are an emergent and promising class of compounds in the fight against MRSA infections.
2025-02-24Current Hypertension Reviews
Efficacy and Safety of Dihydropyridine Calcium Channel Blockers for Primary Hypertension: A Bayesian Network Meta-analysis
Article
作者: Guo, Hao ; Wang, Huiduo ; Zhang, Zhiyong ; Yang, Hongxin
Background::
Dihydropyridine-calcium channel blockers (DHP-CCBs) are effective
first-line blood pressure-lowering agents for primary hypertension. However, data comparing the
variations in efficacy and safety between different types of DHP-CCBs are scarce.
Aims and Objectives::
This study aimed to summarize the latest evidence on the benefits and
harms of seven DHP-CCBs (amlodipine, levamlodipine, felodipine, lacidipine, nitrendipine,
nifedipine, and benidipine).
Methods::
A meta-analysis of DHP-CCBs was carried out to explore differences in efficacy and
safety. We searched PubMed, Embase, the Cochrane Library, CNKI, Wanfang Data, and VIP
databases from inception to September, 2023, for randomized controlled trials (RCTs) comparing
DHP-CCBs. The main outcomes were blood pressure lowering and adverse events (AEs) during
treatment.
Results::
We included 181 RCTs (21,383 patients) in this analysis. In terms of efficacy, levamlodipine
ranked highest in reducing office blood pressure (surface under the cumulative ranking
systolic blood pressure = 80.81%, diastolic blood pressure [DBP] = 82.42%) and 24-h ambulatory
DBP (98.07%). Felodipine had the highest probability of reducing 24-h ambulatory blood pressure
(80.65%). Regarding safety, levamlodipine had the least impact on heart rate (85.71%). In
terms of AEs, benidipine had the highest rate for cardiovascular (86.58%) and digestive system
(93.57%) AEs. Nifedipine and amlodipine had the highest rates of central (80.65%) and peripheral
nervous system (83.28%) AEs, respectively. Levamlodipine exhibited significantly lower rates of
total AEs (1.24%), central nervous system AEs (1.28%), and cardiovascular system AEs (3.62%)
than the other interventions.
Conclusion::
In the office setting, levamlodipine may be the best treatment for primary hypertension,
and lacidipine shows good safety.
100 项与 盐酸贝尼地平 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾实质性高血压 | 日本 | 1994-06-01 | |
| 心绞痛 | 日本 | 1991-10-04 | |
| 高血压 | 日本 | 1991-10-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 3,501 | Benidipine + Thiazide | 膚積鹽壓顧繭簾繭窪衊(築積鹽壓遞鏇鏇襯淵艱) = 膚壓構壓餘積艱鏇齋築 鬱網構餘鬱糧遞範淵夢 (艱餘艱夢選淵簾蓋獵襯 ) 更多 | - | 2020-01-29 | ||
Benidipine + β-blocker | 膚積鹽壓顧繭簾繭窪衊(築積鹽壓遞鏇鏇襯淵艱) = 蓋憲膚糧憲鬱廠齋廠膚 鬱網構餘鬱糧遞範淵夢 (艱餘艱夢選淵簾蓋獵襯 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用